Major drug firms have been telling investors they'll offset patent expirations with...
Major drug firms have been telling investors they'll offset patent expirations with emerging-market growth, although they may be overambitious. Cooling economies and local competition have weakened prospects for the multinationals, with E&Y calculating a $47B difference between companies' sales expectations and what they'll actually earn. Eli Lilly (LLY) and Pfizer (PFE) are among those affected.
From other sites
at Zacks.com (Tue, 10:50AM)
at Zacks.com (Mon, 5:51PM)
at 4-traders.com (Mon, 8:59AM)
at 4-traders.com (Mon, 8:03AM)
at 4-traders.com (Mon, 6:29AM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs